Introduction: One of the major complications in hemodialysis patients is cardiovascular
disease. Lipid abnormality is an important factor in the development of cardiovascular …

Hemodialysis (HD) patients have a high incidence of cardiovascular disease and increased
premature mortality. N-3 polyunsaturated fatty acids (PUFAs) are known to decrease plasma …

Background. Some recent suggestions could show omega-3 condition deficiency following
prolonged hemodialysis; however, these claims and speculations have not been well …

Materials and Methods. Fifty-two hemodialysis patients were divided into 2 groups to receive
omega-3 and placebo for 6 six months. Serum biomarkers and inflammatory agents were …

Objectives: The aim of this study was to evaluate the effect of omega-3 supplementation on
the lipid profile and inflammatory markers in children on chronic hemodialysis. Background …

Background and Aims Studies of omega-3 supplementation in dialysis patients describe
salutary effects on lipid profiles. However, study results have been inconsistent. The aim of …

Objective: A randomized, double-blind, placebo-controlled clinical trial was performed to
assess the effect of omega-3 supplementation (3 g/day) on atherosclerosis progression by …

Background: Lipid abnormalities, especially high serum lipoprotein (a)[Lp (a)] concentration,
and anemia are two major causes of cardiovascular diseases (CVDs) in hemodialysis …

OBJECTIVE: The aim of this study was to test the hypothesis that omega-3 fatty acids have
an effect on serum lipids and inflammation markers in chronic hemodialysis (HD) patients …

Objective We sought to evaluate the effects of omega-3 fatty acids supplementation on
serum lipid profile and oxidative stress markers in pediatric patients with end-stage renal …